Is 0RKL undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0RKL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0RKL (SEK473) is trading below our estimate of fair value (SEK766.12)
Significantly Below Fair Value: 0RKL is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0RKL?
Key metric: As 0RKL is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
The above table shows the Price to Earnings ratio for 0RKL. This is calculated by dividing 0RKL's market cap by their current
earnings.
What is 0RKL's PE Ratio?
PE Ratio
72.9x
Earnings
SEK 204.27m
Market Cap
SEK 14.90b
0RKL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Earnings vs Industry: 0RKL is expensive based on its Price-To-Earnings Ratio (72.9x) compared to the European Medical Equipment industry average (29.6x).
Price to Earnings Ratio vs Fair Ratio
What is 0RKL's PE Ratio
compared to its
Fair PE Ratio?
This is the expected PE Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
0RKL PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio
72.9x
Fair PE Ratio
37.7x
Price-To-Earnings vs Fair Ratio: 0RKL is expensive based on its Price-To-Earnings Ratio (72.9x) compared to the estimated Fair Price-To-Earnings Ratio (37.7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
The above table shows the analyst 0RKL forecast and predictions for the stock price in 12 month’s time.
Date
Share Price
Average 1Y Price Target
Dispersion
High
Low
1Y Actual price
Analysts
Current
SEK 473.00
SEK 538.17
+13.8%
7.8%
SEK 584.00
SEK 480.00
n/a
6
Dec ’25
SEK 471.13
SEK 538.17
+14.2%
7.8%
SEK 584.00
SEK 480.00
n/a
6
Nov ’25
SEK 450.35
SEK 545.67
+21.2%
6.3%
SEK 584.00
SEK 480.00
n/a
6
Oct ’25
SEK 502.00
SEK 549.00
+9.4%
6.6%
SEK 584.00
SEK 480.00
n/a
6
Sep ’25
SEK 530.65
SEK 549.00
+3.5%
6.6%
SEK 584.00
SEK 480.00
n/a
6
Aug ’25
SEK 515.40
SEK 549.00
+6.5%
6.6%
SEK 584.00
SEK 480.00
n/a
6
Jul ’25
SEK 418.50
SEK 440.00
+5.1%
13.9%
SEK 520.00
SEK 340.00
n/a
6
Jun ’25
SEK 431.00
SEK 408.00
-5.3%
12.0%
SEK 468.00
SEK 340.00
n/a
6
May ’25
SEK 381.50
SEK 408.00
+6.9%
12.0%
SEK 468.00
SEK 340.00
n/a
6
Apr ’25
SEK 275.00
SEK 382.60
+39.1%
9.0%
SEK 425.00
SEK 340.00
n/a
5
Mar ’25
SEK 276.31
SEK 382.60
+38.5%
9.0%
SEK 425.00
SEK 340.00
n/a
5
Feb ’25
SEK 284.52
SEK 389.60
+36.9%
7.8%
SEK 425.00
SEK 340.00
n/a
5
Jan ’25
SEK 329.52
SEK 377.00
+14.4%
16.3%
SEK 450.00
SEK 280.00
n/a
5
Dec ’24
SEK 272.76
SEK 363.75
+33.4%
17.1%
SEK 450.00
SEK 280.00
SEK 471.13
4
Nov ’24
SEK 230.73
SEK 371.67
+61.1%
18.8%
SEK 450.00
SEK 280.00
SEK 450.35
3
Oct ’24
SEK 276.44
SEK 391.67
+41.7%
11.5%
SEK 450.00
SEK 340.00
SEK 502.00
3
Sep ’24
SEK 289.50
SEK 391.67
+35.3%
11.5%
SEK 450.00
SEK 340.00
SEK 530.65
3
Aug ’24
SEK 323.00
SEK 376.67
+16.6%
7.2%
SEK 405.00
SEK 340.00
SEK 515.40
3
Jul ’24
SEK 303.55
SEK 376.67
+24.1%
7.2%
SEK 405.00
SEK 340.00
SEK 418.50
3
Jun ’24
SEK 286.57
SEK 376.67
+31.4%
7.2%
SEK 405.00
SEK 340.00
SEK 431.00
3
May ’24
SEK 305.48
SEK 370.00
+21.1%
7.2%
SEK 405.00
SEK 340.00
SEK 381.50
3
Apr ’24
SEK 244.00
SEK 354.00
+45.1%
8.7%
SEK 385.00
SEK 312.00
SEK 275.00
3
Mar ’24
SEK 235.00
SEK 365.50
+55.5%
9.1%
SEK 400.00
SEK 312.00
SEK 276.31
4
Feb ’24
SEK 220.97
SEK 365.50
+65.4%
9.1%
SEK 400.00
SEK 312.00
SEK 284.52
4
Jan ’24
SEK 185.66
SEK 357.50
+92.6%
11.3%
SEK 400.00
SEK 291.00
SEK 329.52
4
Dec ’23
SEK 195.80
SEK 357.50
+82.6%
11.3%
SEK 400.00
SEK 291.00
SEK 272.76
4
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2024/12/23 01:28
End of Day Share Price
2024/12/23 00:00
Earnings
2024/09/30
Annual Earnings
2023/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Xvivo Perfusion AB (publ) is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.